ATC Group: C07AG02 Carvedilol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C07AG02 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C07 Beta blocking agents
3 C07A Beta blocking agents
4 C07AG Alpha and beta blocking agents
5 C07AG02 Carvedilol

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code Route Amount Notes
ORAL Oral 37.5 mg

Active ingredients in C07AG02

Active Ingredient

Carvedilol is a vasodilatory non-selective beta-blocker, which reduces the peripheral vascular resistance by selective alpha1-receptor blockade and suppresses the renin-angiotensin system through non-selective beta-blockade. Plasma renin activity is reduced and fluid retention is rare.

Related product monographs

Document Type Information Source  
 DILATREND Tablet MPI, Generic Health Products Regulatory Authority (ZA)
 EUCARDIC Tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)

Medicines in this ATC group

United States (US)

Albania (AL)

Austria (AT)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Mexico (MX)

New Zealand (NZ)

Nigeria (NG)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.